key: cord-0892959-wgwyvex8
authors: Tsujikawa, Tetsuya; Anzai, Masaki; Umeda, Yukihiro; Tsuyoshi, Hideaki; Kosaka, Nobuyuki; Kimura, Hirohiko; Okazawa, Hidehiko
title: COVID-19 pneumonia detected by [(18)F]FDG PET/MRI: a case with negative antigen test and chest X-ray results
date: 2022-03-09
journal: BJR Case Rep
DOI: 10.1259/bjrcr.20210131
sha: 9c461231c8a6c73fc07c5610ab5a2b638a2ce115
doc_id: 892959
cord_uid: wgwyvex8

Since the outbreak of pneumonia caused by a novel coronavirus (SARS-CoV-2) named Coronavirus disease 2019 (COVID-19) in China, researchers have reported the fluorodeoxyglucose positron emission tomography/CT (FDG PET/CT) manifestations of COVID-19 infection. We present a 37-year-old female with early-stage cervical cancer and fever without a focus who had negative SARS-CoV-2 antigen test and chest X-ray results. FDG PET/MRI performed for preoperative evaluation incidentally detected pneumonia showing high FDG uptake and diffusion-weighted imaging signals in right lung base. She retested positive for SARS-CoV-2 and was diagnosed as having COVID-19 pneumonia. Whole-body PET/MRI can provide multi functional images and could be useful for evaluating the pathophysiology of COVID-19.

We present herein a 37-year-old female with early-stage cervical cancer and fever without a focus lasting for 5 days. She tested negative for SARS-CoV-2 antigen and the chest X-ray was normal ( 

Compared with PET/CT, PET/MRI has several strengths such as improved soft tissue contrast and added value of DWI. 4 On the other hand, limitations of PET/MRI are long scan duration and limited evaluation of pulmonary parenchyma. Although many researchers have recently reported the FDG PET/CT manifestations of COVID-19 infection, [5] [6] [7] to the best of our knowledge, this is the first report showing COVID-19 pneumonia visualized by integrated FDG PET/MRI which simultaneously provides PET and MR functional images. In this case with negative SARS-CoV-2 antigen test and chest X-ray results, incidental high FDG uptake and high DWI signals in the lung aided in the detection of COVID-19 pneumonia. In addition, the use of a metal-free face mask compatible with MRI helped in preventing the dispersal of viral droplets. 8 SARS-CoV-2 uses angiotensin-converting enzyme-2 (ACE-2) as a functional receptor and high ACE-2 expression is known in alveolar type II cells of the lung and many patients infected with COVID-19 develop pneumonia. 9 In some cases, the entry of SARS-CoV-2 into alveolar Type II cells and subsequent proinflammatory cytokine release (cytokine storm) may cause acute respiratory distress syndrome. ACE-2 is also found in the heart, small intestine, arterial and venous endothelial cells and smooth muscle cells in organs including the brain. 10 SARS-CoV-2 infection is a systemic disease that can affect multiple organ systems besides the lungs causing myocardial injury, central nervous system (CNS) and gastrointestinal involvement. 11 12 Currently established molecular targets possibly suitable for COVID-19 are chemokines and chemokine receptors, ACE-2 and the Type 1 angiotensin-II-receptor (ATR1), post-inflammatory fibrosis, purinergic receptor P2X7, cyclooxigenase-2, and CD-8 + T-lymphocytes etc. Integrated PET/MRI using dedicated tracers could prove to be helpful in cases of occult myositis, endocarditis, myocardial inflammation, or myopathy, as well as CNS involvement. Given the still limited availability of PET/MRI and novel PET tracers and current existing demand for this modality, whole-body PET/MRI could be used for evaluating the pathophysiology of COVID-19 as a systemic disease.

• Incidental high FDG uptake and high DWI signals in the lung aid in the detection of COVID-19 pneumonia. • The use of an MRI-safe face mask with no metal helps in preventing the dispersal of viral droplets during PET/MRI scans. • Whole-body PET/MRI could be useful for evaluating the pathophysiology of COVID-19 as a systemic disease. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society

PET/ MRI: Where might it replace PET/CT?

FDG PET/CT findings in an asymptomatic case of confirmed COVID-19

COVID-19: incidental diagnosis by 18F-FDG PET/CT

18F-FDG PET/CT metabolic behavior of COVID-19 pneumonia: a series of 4 patients with RT-PCR confirmation

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

A comprehensive review of imaging findings in COVID-19 -status in early 2021

Quantify. Predict. Why immunologists should widely use molecular imaging for Coronavirus Disease